-
公开(公告)号：US20190241669A1
公开(公告)日：2019-08-08
申请号：US16384719
申请日：2019-04-15
Applicant: Pfizer Inc.
Inventor： Tracy Chia-Chien KUO , Bijan Andre BOLDAJIPOUR , Javier Fernando CHAPARRO RIGGERS , Philippe DUCHATEAU , Roman Ariel GALETTO , Alexandre JUILLERAT , Thomas Charles PERTEL , Arvind RAJPAL , Barbra Johnson SASU , Cesar Adolfo SOMMER , Julien VALTON , Thomas John VAN BLARCOM
IPC: C07K16/28 , C07K14/705 , A61K31/7076 , A61K35/17 , C12N15/63 , C07K14/725 , A61K39/00
CPC classification number: C07K16/2878 , A61K31/7076 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/505 , A61K2039/5156 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C07K16/2863 , C07K16/2896 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C12N15/63
Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
-
公开(公告)号：US20230287120A1
公开(公告)日：2023-09-14
申请号：US18308143
申请日：2023-04-27
Applicant: ALLOGENE THERAPEUTICS, INC. , PFIZER INC.
Inventor： Yi ZHANG , Thomas John VAN BLARCOM , Siler PANOWSKI , Silvia K. TACHEVA-GRIGOROVA , Barbra Johnson SASU
CPC classification number: C07K16/2809 , A61P35/00 , C07K16/2887 , C12N15/63 , A61K2039/505
Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.
-
公开(公告)号：US20210054087A1
公开(公告)日：2021-02-25
申请号：US17005073
申请日：2020-08-27
Applicant: PFIZER INC.
Inventor： Tracy Chia-Chien KUO , Javier Fernando CHAPARRO RIGGERS , Wei CHEN , Amy Shaw-Ru CHEN , Edward Derrick PASCUA , Thomas John VAN BLARCOM , Leila Marie BOUSTANY , Weihsien HO , Yik Andy YEUNG , Pavel STROP , Arvind RAJPAL
IPC: C07K16/28 , A61K39/395 , A61K31/454 , A61K31/704 , A61K31/69 , A61K47/68
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
-
公开(公告)号：US20160297885A1
公开(公告)日：2016-10-13
申请号：US15085644
申请日：2016-03-30
Applicant: PFIZER INC.
Inventor： Tracy Chia-Chien KUO , Javier Fernando CHAPARRO RIGGERS , Wei CHEN , Amy Shaw-Ru CHEN , Edward Derrick PASCUA , Thomas John VAN BLARCOM , Leila Marie BOUSTANY , Weihsien HO , Yik Andy YEUNG , Pavel STROP , Arvind RAJPAL
IPC: C07K16/28 , A61K31/704 , A61K38/07 , A61K38/05 , A61K39/395 , A61K31/454
CPC classification number: C07K16/2878 , A61K31/454 , A61K31/69 , A61K31/704 , A61K39/3955 , A61K39/39558 , A61K47/6801 , A61K47/6849 , A61K2039/505 , C07K16/2803 , C07K16/2809 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , A61K2300/00
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
Abstract translation: 本发明涉及特异性结合BCMA（B细胞成熟抗原）和/或CD3（分化群3）的抗体，例如全长抗体或其抗原结合片段。 本发明还涉及包含BCMA抗体的抗体缀合物（例如，抗体 - 药物偶联物），包含BCMA抗体的组合物，以及使用BCMA抗体及其缀合物治疗与表达BCMA的细胞相关的病症的方法（例如癌症或 自身免疫性疾病）。 本发明还涉及特异性结合CD3和肿瘤细胞抗原的异源多聚体抗体（例如，特异性结合CD3和BCMA的双特异性抗体）。 还提供了包含这种异源多聚体抗体的组合物，用于产生和纯化此类异二聚体抗体的方法及其在诊断和治疗中的应用。
-
公开(公告)号：US20250011446A1
公开(公告)日：2025-01-09
申请号：US18639749
申请日：2024-04-18
Applicant: Pfizer Inc.
Inventor： Siler PANOWSKI , Tao SAI , Barbra Johnson SASU , Surabhi SRIVATSA SRINIVASAN , Thomas John VAN BLARCOM
Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
-
Patent Agency Ranking
公开(公告)号：US20210107979A1
公开(公告)日：2021-04-15
申请号：US16802822
申请日：2020-02-27
Applicant: ALLOGENE THERAPEUTICS, INC. , PFIZER INC.
Inventor： Yi ZHANG , Thomas John VAN BLARCOM , Siler PANOWSKI , Silvia K. TACHEVA-GRIGOROVA , Barbra Johnson SASU
Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.
-
公开(公告)号：US20180171018A1
公开(公告)日：2018-06-21
申请号：US15878344
申请日：2018-01-23
Applicant: PFIZER INC.
Inventor： Tracy Chia-Chien KUO , Javier Fernando CHAPARRO RIGGERS , Wei CHEN , Amy Shaw-Ru CHEN , Edward Derrick PASCUA , Thomas John VAN BLARCOM , Leila Marie BOUSTANY , Weihsien HO , Yik Andy YEUNG , Pavel STROP , Arvind RAJPAL
IPC: C07K16/28 , A61K39/395 , A61K47/68 , A61K31/454 , A61K31/69 , A61K31/704 , A61K39/00
CPC classification number: C07K16/2878 , A61K31/454 , A61K31/69 , A61K31/704 , A61K39/3955 , A61K39/39558 , A61K47/6801 , A61K47/6849 , A61K2039/505 , C07K16/2803 , C07K16/2809 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/92 , A61K2300/00
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
-
公开(公告)号：US20240216430A1
公开(公告)日：2024-07-04
申请号：US18521196
申请日：2023-11-28
Applicant: ALLOGENE THERAPEUTICS, INC. , PFIZER INC.
Inventor： Zhe LI , Siler PANOWSKI , Barbra Johnson SASU , Bryan A. SMITH , Thomas John VAN BLARCOM , Tao SAI , Guoyun ZHU
CPC classification number: A61K35/17 , A61K39/4611 , A61K39/4631 , A61K39/464438 , C07K16/2875 , A61K2039/505 , A61K2239/13 , A61K2239/17 , A61K2239/21 , A61K2239/22 , A61K2239/23 , A61K2239/29 , A61K2239/31 , C07K2317/31 , C07K2317/565 , C07K2317/622
Abstract: Provided herein are Claudin 18.2 binding agents and chimeric antigen receptors (CARs) comprising a Claudin 18.2 binding molecule that specifically binds to Claudin 18.2; and immune cells comprising these Claudin 18.2-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using Claudin 18.2-specific CARs and Claudin 18.2 binding agents, and immune cells comprising Claudin 18.2-specific CARs.
-
公开(公告)号：US20240124591A1
公开(公告)日：2024-04-18
申请号：US18319943
申请日：2023-05-18
Applicant: Pfizer Inc.
Inventor： Javier Fernando CHAPARRO RIGGERS , Shih-Hsun CHEN , Sheng DING , Pawel Kamil DOMINIK , Shahram SALEK-ARDAKANI , Jessica Lynn Stanfield , Thomas John VAN BLARCOM
CPC classification number: C07K16/2827 , A61P35/00 , C07K16/2803 , A61K2039/505
Abstract: Antibodies that specifically bind to CD47 and antibodies that specifically bind to PD-L1 are provided, as well as CD47/PD-L1 bispecific antibodies. Also provided are uses of these antibodies, and related compositions and methods.
-
公开(公告)号：US20210188991A1
公开(公告)日：2021-06-24
申请号：US17129833
申请日：2020-12-21
Applicant: PFIZER INC.
Inventor： Tracy Chia-Chien KUO , Javier Fernando CHAPARRO RIGGERS , Wei CHEN , Amy Shaw-Ru CHEN , Edward Derrick PASCUA , Thomas John VAN BLARCOM , Leila Marie BOUSTANY , Weihsien HO , Yik Andy YEUNG , Pavel STROP , Arvind RAJPAL
IPC: C07K16/28 , A61K39/395 , A61K31/454 , A61K31/704 , A61K31/69 , A61K47/68
Abstract: The present invention relates bispecific antibodies that specific binds to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.019 seconds)
